Showing results (241-250 of 777) with videos related to
Sort By:
Pageof 78
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.Cancer Management and Research|September 8, 2012
Lenalidomide for the treatment of relapsed and refractory multiple myelomaNiels Wcj van de Donk, Güllü Görgün, Richard Wj Groen, et al.Leukemia Research|January 17, 2002
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridolIgor Semenov, Canan Akyuz, Vera Roginskaya, et al.Bone|January 22, 2013
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myelomaSamantha Pozzi, Mariateresa Fulciniti, Hua Yan, et al.British Journal of Haematology|May 30, 2012
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium studyAndrzej J Jakubowiak, Paul G Richardson, Todd Zimmerman, et al.Blood|March 29, 2024
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myelomaAnnamaria Gulla, Eugenio Morelli, Megan Johnstone, et al.British Journal of Haematology|May 8, 2013
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activityMoshe E Gatt, Kohichi Takada, Mala Mani, et al.Blood|September 10, 2005
Dysfunctional T regulatory cells in multiple myelomaRao H Prabhala, Paola Neri, Jooeun E Bae, et al.Seminars in Hematology|March 16, 2004
The role of immunomodulatory drugs in multiple myelomaKenneth C AndersonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2011
Oncogenomics to target myeloma in the bone marrow microenvironmentKenneth C AndersonPageof 78